23andMe

23andMe

生物技术研究

Sunnyvale,California 77,900 位关注者

关于我们

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.

网站
https://www.23andme.com
所属行业
生物技术研究
规模
501-1,000 人
总部
Sunnyvale,California
类型
上市公司
领域
genetic research、consumer genetics、direct-to-consumer genetic testing、telehealth、healthcare、wellness、therapeutics和drug discovery

地点

  • 主要

    223 N Mathilda Ave

    US,California,Sunnyvale,94086

    获取路线
  • 349 Oyster Point Blvd

    US,CA,South San Francisco,94080

    获取路线

23andMe员工

动态

关联主页

相似主页

查看职位

融资

23andMe 共 14 轮

上一轮

上市后股权

US$250,000,000.00

Crunchbase 上查看更多信息